A Phase 2 interventional study of Goldnatriomthiosulphate, MDBGN, parthenolide in Allergic Contact Dermatitis, sponsored by Mekos Laboratories AS. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-02-27.
Sponsored by Mekos Laboratories AS · Phase 2, Interventional, and Diagnostic
It is the purpose of this study to determine the concentration of 3 allergens (goldnatriumthiosulphate, methyldibromoglutharonitrile [MDBGN], parthenolide) for diagnosing allergic contact dermatitis.
The TRUE Test standard panel consists of two tape strips, panel 1 with 11 allergen patches and a negative control and panel 2, with 12 allergen patches. TRUE test panel 1 and 2 contain 23 of the most frequent contact allergens.With these 23 allergens, it is possible to detect about 60-70% of contact allergic reactions. Thus, there is a need for expanding the number of allergens included in TRUE Test in order to detect more contact allergic reactions. Therefore goldnatriumthiosulphate, methyldibromoglutharonitrile and parthenolide are developed for inclusion in a third TRUE Test panel. This study is a dose-response study using 3 dilution series to detect the optimum concentration of the 3 allergens. A phase-III study will be performed afterwards to establish the efficacy and safety of the three allergens.
1,435 studies on the registry are indexed under Dermatitis; 131 are open to participants now.
This study's enrollment of 60 is close to the median of 64 across 1,131 interventional studies indexed under Dermatitis.
Browse Dermatitis studies →Mekos Laboratories AS is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Skin reaction from the 3 patch tests. (Allergic or irritant reaction, grade)
Vehicle (polyvinylpyrrolidone [PVP] or hydroxypropylcellulose [HPC])
This study is completed, as verified in Feb 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mekos Laboratories AS